Daan Gene Co., Ltd.

XSEC:002030 Stock Report

Market Cap: CN¥8.2b

Daan Gene Past Earnings Performance

Past criteria checks 0/6

Daan Gene's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 2% per year.

Key information

-3.4%

Earnings growth rate

-3.4%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate2.0%
Return on equity-9.0%
Net Margin-80.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Daan Gene makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002030 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24930-751586247
30 Jun 241,045-697480269
31 Mar 241,038-295468282
31 Dec 231,181105442302
30 Sep 233,553854896494
30 Jun 235,9062,2211,060585
31 Mar 239,0253,7691,148659
01 Jan 2312,0465,4121,543702
30 Sep 2211,3636,0041,182669
30 Jun 2210,8585,6151,281594
31 Mar 228,6874,1701,345568
01 Jan 227,6643,6181,255509
30 Sep 217,4193,4361,383329
30 Jun 216,6913,2681,167273
31 Mar 217,0923,3911,350200
31 Dec 205,3412,4491,034167
30 Sep 203,8901,549989148
30 Jun 202,715810914135
31 Mar 201,435250559105
31 Dec 191,0989252495
30 Sep 191,06010334188
30 Jun 191,19010334496
31 Mar 191,34310238695
31 Dec 181,47910242599
30 Sep 181,5758946586
30 Jun 181,57588426132
31 Mar 181,58188449114
31 Dec 171,5428747892
30 Sep 171,6099851073
30 Jun 171,5941015700
31 Mar 171,6271075820
31 Dec 161,6131075650
30 Sep 161,6381075030
30 Jun 161,6361054950
31 Mar 161,5361024620
31 Dec 151,4741014390
30 Sep 151,3221333980
30 Jun 151,2231533630
31 Mar 151,1501533490
31 Dec 141,0861533380
30 Sep 141,0161233300
30 Jun 149641473440
31 Mar 149031453190
31 Dec 138541443170

Quality Earnings: 002030 is currently unprofitable.

Growing Profit Margin: 002030 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002030 is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare 002030's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 002030 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).

Return on Equity

High ROE: 002030 has a negative Return on Equity (-9.02%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:36
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daan Gene Co., Ltd. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xing Qiu LinAJ Securities Co., Ltd
Shuchang LiuChangjiang Securities Co. LTD.
Tong ZhangChina Merchants Securities Co. Ltd.